MedTrace Logo

Glooko mHealth Advantage Study

NCT02974816 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2021-06-03

No results posted yet for this study

Summary

The purpose of this study is to compare HbA1c of insulin-treated subjects with type 2 diabetes managed via usual care alone and usual care augmented with remote monitoring using Glooko

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DEVICE

Glooko's mobile application

Standard of care and Remote monitoring

Sponsors & Collaborators

  • Glooko

    lead INDUSTRY

Principal Investigators

  • Michael Greenfield, MD · Glooko

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-15
Primary Completion
2020-04-17
Completion
2020-04-17
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02974816 on ClinicalTrials.gov